2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Laparoscopic Donor Nephrectomy Safety: Experience of 500 Cases in Hispanic Population at a Single Institution
Transplantation Surgery, Colombiana de Trasplantes, Bogota, Colombia.
Background: Laparoscopic live donor nephrectomy (LDN) has become the best option in living donation because its safety and low rate of complications. This report aims…2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…2018 American Transplant Congress
Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients
University of Iowa Hospitals and Clinics, Iowa City, IA.
Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…2018 American Transplant Congress
Pediatric Kidney Transplant in Norway – Results after Switching from Midline to Retroperitoneal Approach in Recipients below 25 kg
Section for Transplant Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Introduction: Pediatric kidney transplants demand a high level of surgical and medical involvement and skill. In Norway, all organ transplants are centralized and performed at…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
Radiation Exposure to the Transplant Surgeon: A Case Study of Recent Yttrium-90 Treatment in an Explanted Liver
BACKGROUND: Yttrium-90 (Y-90) radioembolization for the treatment of hepatocellular carcinoma can present safety challenges to the surgeon when transplanting a recently treated Y-90 patient. To…2018 American Transplant Congress
The First Series of Ischemia-Free Liver Transplantation in Human
BACKGROUND&AIMS: Ischemia and reperfusion injury (IRI) is known as an inevitable event leading to early and late graft failure. We have performed the first case…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 19
- Next Page »